Atrion Corporation Stock Fair Value Calculator – ATRION CORPORATION Reports 10.3% Decrease in Revenue for FY2023 Q2
August 22, 2023
🌥️Earnings Overview
On August 8, 2023, ATRION CORPORATION ($NASDAQ:ATRI) announced its earnings results for Q2 of the 2023 fiscal year, recording a total revenue of USD 43.8 million, a decrease of 10.3% compared to the same quarter of FY2022. Its net income for the quarter was USD 6.6 million, a drop of 29.8% year-on-year.
Analysis – Atrion Corporation Stock Fair Value Calculator
GoodWhale has conducted a thorough analysis of the fundamentals of ATRION CORPORATION. Through our proprietary Valuation Line, we have determined that the intrinsic value of an ATRION CORPORATION share is around $716.7. This reveals that the stock is currently being traded at a price of $557.6, which is significantly undervalued by 22.2%. This presents a great opportunity for investors to accumulate shares in ATRION CORPORATION and benefit from the potential upside. More…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Atrion Corporation. More…
| Total Revenues | Net Income | Net Margin |
| 171.32 | 27.21 | 16.0% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Atrion Corporation. More…
| Operations | Investing | Financing |
| 14.18 | -0.61 | -29.7 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Atrion Corporation. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 266.82 | 25.91 | 136.88 |
Key Ratios Snapshot
Some of the financial key ratios for Atrion Corporation are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 3.4% | -9.1% | 17.6% |
| FCF Margin | ROE | ROA |
| -12.3% | 7.8% | 7.0% |
Peers
In the medical device industry, Atrion Corp competes against LeMaitre Vascular Inc, AtriCure Inc, and Nova Eye Medical Ltd. All four companies offer products that are used to treat cardiovascular diseases. Atrion has a history of innovation, which has allowed it to become a leader in the industry. The company’s competitors have also been successful in their own right, and each offers a unique product portfolio.
– LeMaitre Vascular Inc ($NASDAQ:LMAT)
LeMaitre Vascular Inc is a medical device company that develops, manufactures, and markets vascular devices for the treatment of peripheral vascular disease. Its products are used by vascular surgeons and interventionalists for arterial and venous vessel reconstruction. The company’s products include stents, balloons, and other devices. It has operations in the United States, Europe, Canada, Australia, and Asia.
– AtriCure Inc ($NASDAQ:ATRC)
AtriCure, Inc. is a leading manufacturer of medical devices that provide surgical ablation solutions for the treatment of atrial fibrillation and other cardiac conditions. The company has a market cap of 2.14B as of 2022 and a Return on Equity of -7.05%. AtriCure’s products are sold in over 50 countries and are backed by a strong clinical evidence base. The company’s mission is to improve the lives of patients by providing minimally invasive solutions that treat cardiac conditions with fewer complications and shorter hospital stays.
– Nova Eye Medical Ltd ($ASX:EYE)
Nova Eye Medical Ltd is a publicly traded company that provides ophthalmic products and services. As of 2022, the company had a market capitalization of 40.84 million and a return on equity of -18.79%. Nova Eye Medical Ltd offers a variety of ophthalmic products and services, including cataract surgery, refractive surgery, ocular implants, and more. The company has a presence in both the United States and Canada.
Summary
ATRION CORPORATION’s financial results for FY2023 Q2 were below expectations, with total revenue of USD 43.8 million representing a 10.3% decrease compared to the same quarter of the previous year. Net income also decreased by 29.8% year over year. Despite this, the stock price moved up the same day, suggesting that investors remain optimistic about the company’s future prospects.
It is likely that shareholders have looked to ATRION’s strong track record of performance in the last few years and are confident that the company will be able to rebound from this latest setback. Investors looking to invest in ATRION CORPORATION should continue to monitor the company’s financial performance and assess the potential upside and downside risks associated with investing in the company.
Related Posts
Recent Posts
